Eva1 Targeted CAR T Cells Successfully Eliminate Tumors in Preclinical Study

Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside

Immunotherapy has rapidly evolved in the past decades in the battle against cancer. Chimeric antigen receptor (CAR)-engineered T cells have demonstrated significant success in certain hematologic malignancies, although they still face certain limitations, including high costs and toxic effects. Natural killer cells (NK cells), as a vital component of the immune system, serve as the “first responders” in the context of cancer development. In this…

Eva1 targeted CAR T cells successfully eliminate tumors in preclinical study

CAR-T cells are specialized immune cells genetically modified to recognize and attack cancer cells. Researchers at Nagoya University in Japan and their collaborators have developed new CAR-T cells to target malignant tumors.

Modified CAR-T cells target widespread protein found in multiple types of cancer

CAR-T cells are specialized immune cells genetically modified to recognize and attack cancer cells. Researchers at Nagoya University in Japan and their collaborators have developed new CAR-T cells to target malignant tumors. While similar treatments have worked well for blood cancers, treating solid tumors is more difficult. Their method, published in the Journal for ImmunoTherapy of Cancer, targeted a protein found in high amounts on many types…

AI quantifies brain changes from post-CAR-T cell therapy complication

Researchers recently explored the use of a deep-learning algorithm to quantify ICANS neurotoxicity following CAR T-cell therapy.

Researchers Develop Innovative Tumor-Targeting System to Enhance

In a pioneering stride toward conquering some of the most challenging cancers, researchers at Nagoya University in Japan, in collaboration with international partners, have developed a next-generation CAR-T cell therapy that shows remarkable promise in targeting and eradicating solid tumors. Published in the Journal for ImmunoTherapy of Cancer, this innovative approach harnesses the molecular target Eva1 (also known as MPZL2), a protein prevalen…